Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
ProQR Therapeutics N.V. is a clinical-stage biotechnology company focused on the discovery and development of RNA-based therapeutics. The company operates within the biotechnology and RNA therapeutics industries, with a strategic emphasis on RNA editing technologies designed to address severe genetic and rare diseases. ProQR’s core innovation is its proprietary Axiomer® RNA editing platform, which is designed to precisely edit RNA transcripts to restore or modify protein function without permanently altering DNA.
The company’s primary value driver is its pipeline of preclinical and clinical-stage RNA editing programs targeting inherited retinal, neurological, and metabolic disorders. ProQR serves specialized healthcare markets, primarily patients with rare or orphan diseases, as well as pharmaceutical partners seeking next-generation RNA technologies. Founded in 2012, ProQR evolved from early RNA repair research into a broader RNA editing strategy following clinical setbacks in earlier RNA-targeted programs, leading to a strategic pivot toward platform-based therapeutics.
Business Operations
ProQR operates as a single reporting segment focused on RNA therapeutics research and development, with revenue generation currently driven primarily by collaboration agreements rather than product sales. Its operations center on the development of Axiomer® RNA editing programs, which leverage endogenous ADAR enzymes to enable targeted RNA modifications. The company does not yet have commercialized products and remains in the clinical and preclinical development stage.
Operationally, ProQR conducts research internally while also engaging in strategic collaborations to advance and validate its technology. A notable partnership includes a research collaboration with Eli Lilly and Company, aimed at discovering RNA editing therapies for genetically defined diseases. ProQR operates through its wholly owned subsidiary ProQR Therapeutics I B.V., which supports research and development activities.
Strategic Position & Investments
ProQR’s strategic direction is centered on establishing Axiomer® as a scalable and versatile RNA editing platform applicable across multiple disease areas. Growth initiatives include expanding its internal pipeline, advancing lead candidates into clinical development, and forming partnerships with large pharmaceutical companies to co-develop therapies and generate non-dilutive funding.
The company has not completed any major acquisitions based on available public disclosures, instead prioritizing internal R&D investment and platform expansion. ProQR’s collaboration with Eli Lilly and Company represents its most significant external strategic investment to date, providing validation of its RNA editing approach. The company is actively involved in emerging RNA technologies, particularly site-specific RNA editing as an alternative to gene therapy and genome editing.
Geographic Footprint
ProQR is headquartered in Leiden, the Netherlands, with additional operational presence in Cambridge, Massachusetts, reflecting its transatlantic research and corporate structure. Its activities span Europe and North America, with research, clinical development, and corporate functions distributed across these regions.
While the company does not yet have commercial operations, its clinical development programs and partnerships give it an international footprint, particularly through regulatory engagement and potential future trials in the United States and European Union. ProQR’s strategic collaborations further extend its influence into global pharmaceutical development networks.
Leadership & Governance
ProQR was co-founded by Daniel de Boer, who continues to serve as Chief Executive Officer, shaping the company’s long-term strategy around RNA editing innovation. The leadership team emphasizes scientific rigor, platform scalability, and disciplined capital allocation as core elements of its governance philosophy.
Key executives include:
- Daniel de Boer – Chief Executive Officer
- Janice Storch – Chief Financial Officer
- Michael Cox – Chief Medical Officer
- Garrett Hampton – Chief Scientific Officer
The company is governed by a board of directors with experience in biotechnology, finance, and pharmaceutical development, supporting ProQR’s focus on advancing novel RNA-based therapies through clinical and strategic milestones.